Towards Interpretable Drug-Drug Interaction Prediction: A Graph-Based Approach with Molecular and Network-Level Explanations

Drug-drug interactions (DDIs) represent a critical challenge in pharmacology, often leading to adverse drug reactions with significant implications for patient safety and healthcare outcomes. While graph-based methods have achieved strong predictive performance, most approaches treat drug pairs independently, overlooking the complex, context-dependent interactions unique to drug pairs. Additionally, these models struggle to integrate biological interaction networks and molecular-level structures to provide meaningful mechanistic insights. In this study, we propose MolecBioNet, a novel graph-based framework that integrates molecular and biomedical knowledge for robust and interpretable DDI prediction. By modeling drug pairs as unified entities, MolecBioNet captures both macro-level biological interactions and micro-level molecular influences, offering a comprehensive perspective on DDIs. The framework extracts local subgraphs from biomedical knowledge graphs and constructs hierarchical interaction graphs from molecular representations, leveraging classical graph neural network methods to learn multi-scale representations of drug pairs. To enhance accuracy and interpretability, MolecBioNet introduces two domain-specific pooling strategies: context-aware subgraph pooling (CASPool), which emphasizes biologically relevant entities, and attention-guided influence pooling (AGIPool), which prioritizes influential molecular substructures. The framework further employs mutual information minimization regularization to enhance information diversity during embedding fusion. Experimental results demonstrate that MolecBioNet outperforms state-of-the-art methods in DDI prediction, while ablation studies and embedding visualizations further validate the advantages of unified drug pair modeling and multi-scale knowledge integration. Moreover, the pooling strategies yield interpretable insights into the underlying interaction mechanisms, highlighting MolecBioNet's potential as a robust and transparent framework for predictive modeling in support of drug safety assessment.